{"id":"optimized-antiparkinsonian-treatment","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL7257","moleculeType":"Small molecule","molecularWeight":"218.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without a specific drug name or molecular identifier, this appears to be AbbVie's optimized treatment approach for Parkinson's disease, likely involving combination therapy or dosing optimization of existing antiparkinsonian agents. The actual mechanism would depend on the specific active pharmaceutical ingredient(s) included in the optimized regimen.","oneSentence":"This is a descriptive label for an optimized antiparkinsonian treatment regimen rather than a single drug entity with a defined mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:24:34.388Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT02799381","phase":"PHASE3","title":"A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-09","conditions":"Parkinson's Disease (PD)","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Optimized antiparkinsonian treatment","genericName":"Optimized antiparkinsonian treatment","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a descriptive label for an optimized antiparkinsonian treatment regimen rather than a single drug entity with a defined mechanism. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}